Abstract
The medical management of inflammatory bowel disease in the new millennium requires integrating cost concerns with the efficacy and safety profiles of the expanded therapeutic options available in order to achieve optimal patient outcome.
MeSH terms
-
Anti-Inflammatory Agents, Non-Steroidal / economics
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
-
Colitis, Ulcerative / drug therapy*
-
Colitis, Ulcerative / economics
-
Cost-Benefit Analysis
-
Crohn Disease / drug therapy*
-
Crohn Disease / economics
-
Disease Management*
-
Drug Costs
-
Humans
-
Immunosuppressive Agents / economics
-
Immunosuppressive Agents / therapeutic use*
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Immunosuppressive Agents